MONTREAL, Oct. 29 /CNW Telbec/ - In keeping with its commitment to extend
and enhance the lives of Canadians through ongoing innovation, Bristol-Myers
Squibb Canada (BMS) announced today the commercialization of its innovative
cancer medication ERBITUX(TM) (cetuximab). This news is extremely important to
Canadian physicians and their patients suffering from colorectal cancer who
have exhausted other available treatments because it will give them a new
option to fight this deadly disease.
